5-HT6 and NMDA Antagonist Combination for Cognitive Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive disorders such as Alzheimer's disease are inadequate, with existing therapies providing limited relief and significant burdens on caregivers and patients, necessitating the development of more effective and safer treatment options that can improve cognitive function without the need for institutional care.
Innovation Solution
A combination therapy using pure 5-HT6 receptor antagonists, such as 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole, in conjunction with NMDA receptor antagonists like memantine, which demonstrates synergistic effects in enhancing cognitive function by increasing acetylcholine and glutamate levels, thereby improving therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NMDA receptor antagonists like memantine are used alone, then they provide moderate efficacy in treating moderate to severe Alzheimer's disease, but they do not alter cognitive ability or delay the onset of AD and have unknown effects in initial stages
Solution Approach 1:
The patent combines a 5-HT6 receptor antagonist with an NMDA receptor antagonist (memantine) into a single pharmaceutical composition. This combination therapy leverages the cognitive-enhancing effects of 5-HT6 antagonism alongside the glutamatergic modulation of NMDA antagonism, producing synergistic therapeutic effects that exceed the sum of individual treatments and address both moderate-to-severe and early-stage cognitive symptoms
2Reliability
If cholinesterase inhibitors are used to treat cognitive manifestations, then they provide therapeutic relief, but they cause peripheral side effects
Solution Approach 1:
The patent extracts and targets the central 5-HT6 receptor specifically, which is exclusively expressed in brain areas associated with cognition (hippocampus and frontal cortex). By focusing therapeutic action on this centrally-located receptor without peripheral distribution, the treatment achieves cognitive enhancement while minimizing the peripheral side effects characteristic of cholinesterase inhibitors
3Reliability
If 5-HT6R antagonists are used to improve cognitive function, then they elevate glutamatergic neurotransmission and acetylcholine release, but the mechanism involves complex interactions with both cholinergic and glutamatergic systems
Solution Approach 1:
The patent combines two mechanisms of action into one formulation: 5-HT6 receptor antagonism (which elevates both glutamate and acetylcholine) and NMDA receptor antagonism (which modulates glutamatergic transmission). This unified approach simplifies the complex neurochemical interactions by coordinating both pathways simultaneously, producing reliable cognitive enhancement through synergistic rather than conflicting mechanisms
Data Source
AI summary
The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further relates to the pharmaceutical composition containing the said combination.